Loading clinical trials...
Loading clinical trials...
The primary purpose of this study is to study the side effects of PF-00299804 and determine the highest dose that can be safely administered in patients with advanced cancer.
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
Pfizer
NCT03206060 · Pheochromocytoma, Paraganglioma, and more
NCT06608446 · Breast Neoplasms
NCT07542041 · Pancreatic Cancer, Pancreatic Neoplasms, and more
NCT07541924 · Colorectal Cancer Screening, Colonic Polyps/Colonoscopy/Colorectal Neoplasms, and more
NCT04389632 · Carcinoma, Non-Small Cell Lung, Squamous Cell Carcinoma of Head and Neck, and more
Ronald Reagan UCLA Medical Center
Los Angeles, California
UCLA Hematology/Oncology
Los Angeles, California
UCLA Oncology Center
Los Angeles, California
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions